Arena Pharmaceuticals, Inc. Proceeds from Stock Options Exercised
Arena Pharmaceuticals, Inc. reported Proceeds from Stock Options Exercised of $52.10 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2021-02-23
- Arena Pharmaceuticals, Inc. proceeds from stock options exercised for the quarter ending 2012-12-31 was $500.00K.
- Arena Pharmaceuticals, Inc. proceeds from stock options exercised for the quarter ending 2012-09-30 was $3.20M.
- Arena Pharmaceuticals, Inc. proceeds from stock options exercised for fiscal 2020 was $52.10M, a 242.76% increase from fiscal 2019.
- Arena Pharmaceuticals, Inc. proceeds from stock options exercised for fiscal 2019 was $15.20M, a 157.63% increase from fiscal 2018.
- Arena Pharmaceuticals, Inc. proceeds from stock options exercised for fiscal 2018 was $5.90M, a 9.26% increase from fiscal 2017.
- Arena Pharmaceuticals, Inc. proceeds from stock options exercised for fiscal 2017 was $5.40M.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2020-12-31 | $52.10M 10-K · filed 2021-02-23 | |||
| 2019-12-31 | $15.20M 10-K · filed 2020-02-27 | |||
| 2018-12-31 | $5.90M 10-K · filed 2019-02-28 | |||
| 2017-12-31 | $5.40M 10-K · filed 2018-03-14 | |||
| 2015-12-31 | $2.20M 10-K · filed 2016-02-29 | |||
| 2014-12-31 | $4.10M 10-K · filed 2015-03-02 | |||
| 2013-12-31 | $2.40M 10-K · filed 2014-03-03 | |||
| 2012-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $3.70M derived: sum of 2 quarters · filed 2013-03-01 | $4.70M 10-K · filed 2013-03-01 | |
| 2012-09-30 | $3.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $4.20M 10-Q · filed 2012-11-09 | ||
| 2012-06-30 | $1.00M 10-Q · filed 2012-08-09 |